Healthcare M&A Is Shrinking. Who’s Still Buying?

Good morning, ! Today we're covering the FDA's new Alzheimer's prevention initiative, EQT's $12.1B QIAGEN take-private, the slowdown in healthcare M&A deal values, and Big Pharma's latest billion-dollar bets on next-generation therapeutics.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

DA Launches Alzheimer’s Prevention Initiative: Neuroscience R&D Faces a New Regulatory Playbook

The FDA launched the Neuroscience Advancement and Innovation Nexus (NAIN), introducing a coordinated regulatory approach across drugs, biologics, and medical devices, with Alzheimer’s prevention as its first priority. The initiative aims to address longstanding barriers in neuroscience development, particularly clinical trial design, biomarkers, and evidence requirements for therapies targeting disease before cognitive decline becomes apparent.

So What? For biopharma investors and healthcare leaders, this could shift capital toward early intervention, biomarker platforms, and preventive therapeutics, potentially improving development economics in a historically high-risk market, although faster approvals and commercial returns remain unproven. (More)

It's time to set up your holiday streaming campaign

Are you ready to reach holiday shoppers on CTV? For many streamers, the season is already underway.

Last year, holiday content searches on Roku saw an 86% increase during October. And in November, those searches rise an average of 39% weekly. This surging holiday spirit is mirrored by consumer activity, as about half of Roku streamers shopped Black Friday and Cyber Monday deals in 2025.

Meeting those shoppers is easier than you might think. Begin with the seasonal outcome you hope to drive: awareness, online sales, leads, store visits, or another measurable goal. From there, define your audience, upload your creative, set the budget and campaign dates, and establish measurement before launching. You can even create a shoppable ad unit that lets streamers buy with a click of their remote.

Our holiday playbook offers a month-by-month guide to reaching shoppers during this all-important time of year.

First-time spenders get a $5,000 match on the first $5,000 spent with code BEEHIIV5K. Terms apply.

Launch your campaign today.

TREND TO WATCH

Healthcare M&A: Deal Volume Holds, but Capital Pulls Back

Healthcare dealmaking is showing a growing disconnect between transaction volume and deal value. While activity remained relatively stable at approximately 420 deals per half-year throughout 2024 and 2025, aggregate deal value fluctuated sharply, peaking near $42B in H1 2025 before declining in subsequent periods.

The divergence became more pronounced in H1 2026, when deal volume fell to roughly 370 transactions, while total value dropped to approximately $9B, its lowest level in the period shown.

The subsector mix reveals another important signal. Healthcare services continue to dominate transaction activity, while healthcare IT and digital health maintain a meaningful share of deal flow. The market appears to be supporting smaller transactions even as larger capital commitments become less consistent.

Why it matters: For private equity investors and strategic acquirers, the widening gap between deal count and value suggests a more selective M&A environment. Smaller acquisitions, platform expansion, and targeted consolidation may offer more actionable opportunities than large transformational transactions.

Bottom line: Healthcare M&A has not stopped. But capital deployment is becoming more selective, and deal size increasingly matters as much as deal volume. (More)

DEALS TRACKER

Roche → Hansoh Pharma ADC portfolio (license) | $400M upfront + >$15B milestones
This is Roche's second ADC deal with Hansoh and one of the largest China out-licensing deals ever by milestone value. Read more

HealthSpan Partners → Surgery Partners | ~$5.7B EV
HealthSpan agreed to take Surgery Partners private at $23.50/share, creating a large outpatient surgical care platform. Read more

Merck KGaA, Darmstadt, Germany → Silence Therapeutics | ~$1.3B
Merck KGaA agreed to buy Silence for $20.00/ADS in cash, a 130% premium, adding an siRNA platform to its rare-disease pipeline. Read more

Gilead → PepStar's oral IL-23R program (HCXT-2001) | ~$1.28B (per Reuters)
Gilead agreed to buy a clinical-stage oral IL-23R peptide for IBD, where companies are racing to replace injectable biologics with pills. Read more

DEAL OF THE WEEK

EQT's $12.1 Billion Bet on Life Sciences

EQT has agreed to acquire QIAGEN in a $12.1 billion take-private deal, marking one of the largest life sciences buyouts of 2026.

The Swedish private equity firm, alongside co-investors ADIA and CPP Investments, will offer €46.50 per share in cash, representing a 40.3% premium to QIAGEN's unaffected share price. The transaction is expected to close in mid-2027, subject to regulatory and shareholder approvals.

QIAGEN specializes in molecular diagnostics, sample preparation, and genetic testing technologies used by research laboratories and healthcare providers worldwide.

For EQT, the acquisition provides exposure to a critical segment of healthcare infrastructure, where recurring laboratory demand, technological barriers, and established customer relationships support long-term growth. (More)

INTERESTING ARTICLES